Danaher Corporation (DHR)
| Market Cap | 155.00B +5.6% |
| Revenue (ttm) | 25.11B +4.6% |
| Net Income | 4.00B +17.3% |
| EPS | 5.63 +19.6% |
| Shares Out | 702.99M |
| PE Ratio | 39.15 |
| Forward PE | 24.84 |
| Dividend | $1.60 (0.73%) |
| Ex-Dividend Date | Sep 30, 2026 |
| Volume | 1,331,357 |
| Open | 220.72 |
| Previous Close | 219.81 |
| Day's Range | 219.11 - 221.00 |
| 52-Week Range | 160.93 - 242.80 |
| Beta | 0.80 |
| Analysts | Strong Buy |
| Price Target | 241.00 (+9.3%) |
| Earnings Date | Oct 21, 2026 |
About DHR
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufact... [Read more]
Financial Performance
In 2025, Danaher's revenue was $24.57 billion, an increase of 2.90% compared to the previous year's $23.88 billion. Earnings were $3.61 billion, a decrease of -7.31%.
Financial StatementsAnalyst Summary
According to 25 analysts, the average rating for DHR stock is "Strong Buy." The 12-month stock price target is $241.0, which is an increase of 9.30% from the latest price.
News
Danaher price target raised to $240 from $220 at Morgan Stanley
Morgan Stanley analyst Kallum Titchmarsh raised the firm’s price target on Danaher (DHR) to $240 from $220 and keeps an Overweight rating on the shares.
Danaher price target raised to $255 from $230 at BofA
BofA raised the firm’s price target on Danaher (DHR) to $255 from $230 and keeps a Buy rating on the shares. The life science tools sector has further re-rated since…
Life sciences firm Danaher to launch AI-powered autonomous research lab in 2027
Life sciences company Danaher said on Wednesday it plans to launch its first AI-powered autonomous research lab early next year to make drug discovery and development faster and more efficient.
Danaher plans to launch its first AI-powered autonomous lab in 2027
Danaher (DHR) announced plans to launch its first AI-powered autonomous lab, designed to help researchers develop custom antibodies and other molecular tools faster and more efficiently. Expected to o...
Danaher Accelerates Life Sciences Research with New AI-powered Autonomous Lab
Helping researchers to move from discovery to breakthrough up to 8x faster by combining AI, automation and innovation from across Danaher's ecosystem of industry-leading technologies WASHINGTON, Oct. ...
Danaher price target raised to $255 from $230 at Barclays
Barclays raised the firm’s price target on Danaher (DHR) to $255 from $230 and keeps an Overweight rating on the shares. The firm adjusted targets in the life science and…
Danaher price target raised to $250 from $215 at RBC Capital
RBC Capital analyst Dan Leonard raised the firm’s price target on Danaher (DHR) to $250 from $215 and keeps an Outperform rating on the shares. The firm notes that its…
Danaher price target raised to $250 from $200 at Guggenheim
Guggenheim analyst Subbu Nambi raised the firm’s price target on Danaher (DHR) to $250 from $200 and keeps a Buy rating on the shares. The firm adjusted its models and…
Danaher says Julie Sawyer Montgomery assumes President and CEO role
Danaher (DHR) announced that, effective October 1, Julie Sawyer Montgomery has assumed the roles of President and CEO and has joined Danaher’s Board of Directors, as previously announced on August…
Julie Sawyer Montgomery Assumes Role as Danaher President and Chief Executive Officer
WASHINGTON, Oct. 1, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or "the Company") announced that, effective today, Julie Sawyer Montgomery has assumed the roles of President and Ch...
The Top HealthTech Questions Landing on Our Desks
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled th...
MaxCyte appoints Kapileshwar as Chief Corporate Development Officer
MaxCyte (MXCT) announced that it has appointed Sidharth Kapileshwar as Chief Corporate Development Officer. Kapileshwar joins MaxCyte from Danaher (DHR), where he most recently served as Vice Presiden...
Danaher Schedules Third Quarter 2026 Earnings Conference Call
WASHINGTON, Sept. 22, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2026 on Wednesday, October 21, 20...
Danaher’s IDT, Aldevron launch research grade S.p. Cas9 mRNA, SpyFi
Danaher (DHR) companies Integrated DNA Technologies, IDT, and Aldevron announced the launch of research grade S.p. Cas9 mRNA in wild type and SpyFi high-fidelity formats. The new offering gives resear...
Danaher Announces Quarterly Dividend
WASHINGTON, Sept. 15, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common s...
Danaher assumed with a Buy at UBS
UBS assumed coverage of Danaher (DHR) with a Buy rating and $250 price target Danaher’s latest bioprocessing setback has tested investor patience, but the selloff creates an attractive risk/reward as…
Why Moderna's Cancer Vaccine Matters to Investors
Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not ...
Danaher names Julie Sawyer Montgomery as CEO
Danaher (DHR) announced that the company’s Board of Directors has appointed Julie Sawyer Montgomery as President and CEO and a member of the Board of Directors, effective October 1. On…
Danaher Appoints Julie Sawyer Montgomery as President and Chief Executive Officer
Rainer Blair to retire WASHINGTON, Aug. 3, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or "the Company") announced that the Company's Board of Directors has appointed Julie Sawyer ...
Danaher’s recent volatility presents buying opportunity, says Argus
Argus keeps a Buy rating on Danaher (DHR) with a price target of $230 but notes that the recent trading volatility in the shares presents a buying opportunity. The company…
Danaher price target lowered to $240 from $250 at Deutsche Bank
Deutsche Bank analyst Justin Bowers lowered the firm’s price target on Danaher (DHR) to $240 from $250 and keeps a Buy rating on the shares following the Q2 report. Published…
Don't Quit on Danaher Stock After Horrific Earnings Reaction
There's reason to believe the stock can stage a comeback after its worst day in two decades.
Danaher's revenue outlook cut, biotech miss overshadow profit forecast raise
Danaher raised its annual profit forecast on Tuesday, but shares fell nearly 12% in premarket trading after the life sciences firm trimmed its core revenue growth outlook and reported weaker-than-exp...
Danaher Earnings Call Transcript: Q2 2026
Q2 saw better-than-expected revenue, earnings, and cash flow, with strong life sciences and diagnostics performance. Raised full-year core revenue and EPS guidance, closed Masimo acquisition early, and saw robust order growth despite bioprocessing shipment delays.
Danaher Quarterly report: Q2 2026
Danaher has published its Q2 2026 quarterly earnings report on July 21, 2026.